Stay updated on Switch Maintenance in Pancreatic Clinical Trial
Sign up to get notified when there's something new on the Switch Maintenance in Pancreatic Clinical Trial page.

Latest updates to the Switch Maintenance in Pancreatic Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study record was revised to Phase Ib Open-Label, Multicenter, non-randomized design evaluating switch maintenance using AB154, AB122, and Sotigalimab in metastatic pancreatic cancer, with Massachusetts as a participating location. Eligibility criteria were updated to exclude germline BRCA mutations, and endpoints now include PFS2.SummaryDifference1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedPage revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check49 days agoChange DetectedNotice about lapse in government funding and NIH/Center for Operations status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange DetectedThe new screenshot shows minor layout adjustments and an updated last updated date, while core study details, eligibility criteria, endpoints, and enrollment remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check92 days agoChange DetectedAdded a government funding/status notice and updated version to v3.2.0; removed old v3.1.0 tag.SummaryDifference2%

- Check99 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0 and added a contact phone number (617-632-6073).SummaryDifference0.1%

Stay in the know with updates to Switch Maintenance in Pancreatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switch Maintenance in Pancreatic Clinical Trial page.